Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
Status:
Completed
Trial end date:
2019-04-15
Target enrollment:
Participant gender:
Summary
The goal of this study is to preliminarily determine/estimate feasibility and whether
frequent and early conivaptan use, at a dose currently determined to be safe (i.e.,
40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral
hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether
conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This
study is also an essential first step in understanding the role of conivaptan in CE
management.
Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and
well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and
pressure.